AtriCure to Participate at the Canaccord 41st Annual Growth Conference
30 July 2021 - 10:00PM
Business Wire
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments for atrial fibrillation (Afib) and left atrial appendage
(LAA) management, today announced that the company will be
participating in the upcoming Canaccord 41st Annual Growth
Conference.
AtriCure’s management is scheduled to present on Wednesday,
August 11, 2021, at 8:00 a.m. Eastern Time. Interested parties may
access a live and archived audio webcast of the presentation by
visiting the “Investors” section of the company’s website at
https://ir.atricure.com.
About AtriCure
AtriCure, Inc. provides innovative technologies for the
treatment of Afib and related conditions. Afib affects more than 33
million people worldwide. Electrophysiologists and cardiothoracic
surgeons around the globe use AtriCure technologies for the
treatment of Afib and reduction of Afib related complications.
AtriCure’s Isolator® Synergy™ Ablation System is the first medical
device to receive FDA approval for the treatment of persistent
Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System
products are the most widely sold LAA management devices worldwide.
AtriCure’s Hybrid AFTM Therapy is a minimally invasive procedure
that provides a lasting solution for long-standing persistent Afib
patients. AtriCure’s cryoICE cryoSPHERE® probe is cleared for
temporary ablation of peripheral nerves to block pain, providing
pain relief in cardiac and thoracic procedures. For more
information, visit AtriCure.com or follow us on Twitter
@AtriCure.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210730005031/en/
Angie Wirick AtriCure, Inc. Chief Financial Officer (513)
755-5334 awirick@atricure.com Lynn Pieper Lewis Gilmartin Group
Investor Relations (415) 937-5402 lynn@gilmartinir.com
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Apr 2024 to May 2024
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From May 2023 to May 2024